EUVIMEDEUVIMED entdecken
FallberichtOpen Access · CC BY 4.0

Case Report: Lenalidomide as a novel maintenance therapy for metastatic follicular dendritic cell sarcoma

Saarang Kashyap, Esha Sankhala, Jordan Ziegler, Rebecca Godin, Ivan Huang, James Heeter, Spencer Rosant, Kamlesh K Sankhala

Frontiers in Oncology · 14.05.2026 · 16

DOI: 10.3389/fonc.2026.1801801 ↗

Kurz gefasst

Fallbericht in der Zeitschrift Frontiers in Oncology, online erschienen am 14.05.2026. Verfasst von Saarang Kashyap und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, United States. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Follicular dendritic cell sarcoma (FDCS) is a rare, low- to intermediate-grade malignancy arising from mesenchymal-derived follicular dendritic cells, which can also present with high-grade pathological features and may rapidly become fatal. Conventional therapeutic strategies, primarily consisting of surgical resection with adjunctive systemic chemotherapy, such as gemcitabine-docetaxel, ifosfamide, doxorubicin, or other regimens, remain inconsistently effective, with median survival notably reduced in advanced or recurrent disease. Given the limited therapeutic options and frequent relapse, there is a critical need for well-tolerated treatments that can improve long-term outcomes for patients with metastatic FDCS. Here, we report the first documented clinical use of the immunomodulatory agent lenalidomide (Revlimid) as maintenance therapy for FDCS following chemotherapy. Remarkably, the patient achieved nearly total sustained remission with exceptional disease stabilization for approximately seven years, experiencing only one manageable recurrence. This clinical response points to lenalidomide as a promising maintenance therapy for metastatic FDCS and may provide further basis for consideration of lenalidomide as a refractory treatment.

Schlagwörter

Stichwörter der Autor:innen

follicular dendritic cell sarcoma (FDCS)immunomodulatoryimmunotherapylenalidomidemaintenance therapy (MT)metastatic

Autor:innen und Institutionen

  • Department of Microbiology, Immunology & Molecular Genetics, University of California, Los Angeles, Los Angeles, CA, United States.
  • University of Queensland, Brisbane, QLD, Australia.
  • Precision Next Gen Oncology and Research Center, Los Angeles, CA, United States.
  • Department of Physiological Science, University of California, Los Angeles, Los Angeles, CA, United States.
  • Department of Chemistry and Biochemistry, University of California, Los Angeles, Los Angeles, CA, United States.
  • Department of Biology, University of California, Los Angeles, Los Angeles, CA, United States.

Zitieren

APA

Kashyap, S., Sankhala, E., Ziegler, J., Godin, R., Huang, I., Heeter, J., Rosant, S., & Sankhala, K. K. (2026). Case Report: Lenalidomide as a novel maintenance therapy for metastatic follicular dendritic cell sarcoma. Frontiers in Oncology, 16. https://doi.org/10.3389/fonc.2026.1801801

Vancouver

Kashyap S, Sankhala E, Ziegler J, Godin R, Huang I, Heeter J, et al. Case Report: Lenalidomide as a novel maintenance therapy for metastatic follicular dendritic cell sarcoma. Frontiers in Oncology. 2026;16. doi:10.3389/fonc.2026.1801801

BibTeX
@article{Kashyap2026,
  author = {Kashyap, Saarang and Sankhala, Esha and Ziegler, Jordan and Godin, Rebecca and Huang, Ivan and Heeter, James and Rosant, Spencer and Sankhala, Kamlesh K},
  title = {Case Report: Lenalidomide as a novel maintenance therapy for metastatic follicular dendritic cell sarcoma},
  journal = {Frontiers in Oncology},
  year = {2026},
  volume = {16},
  doi = {10.3389/fonc.2026.1801801}
}
Kostenlos starten →